CN116528864A - 杂芳基甲酰胺化合物 - Google Patents
杂芳基甲酰胺化合物 Download PDFInfo
- Publication number
- CN116528864A CN116528864A CN202180080083.8A CN202180080083A CN116528864A CN 116528864 A CN116528864 A CN 116528864A CN 202180080083 A CN202180080083 A CN 202180080083A CN 116528864 A CN116528864 A CN 116528864A
- Authority
- CN
- China
- Prior art keywords
- methyl
- compound
- phenyl
- alkyl
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020197899 | 2020-11-30 | ||
| JP2020-197899 | 2020-11-30 | ||
| PCT/JP2021/043540 WO2022114164A1 (ja) | 2020-11-30 | 2021-11-29 | ヘテロアリールカルボキシアミド化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116528864A true CN116528864A (zh) | 2023-08-01 |
Family
ID=81754515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180080083.8A Pending CN116528864A (zh) | 2020-11-30 | 2021-11-29 | 杂芳基甲酰胺化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240043403A1 (https=) |
| EP (1) | EP4253373A4 (https=) |
| JP (1) | JP7397452B2 (https=) |
| KR (1) | KR20230116838A (https=) |
| CN (1) | CN116528864A (https=) |
| AR (1) | AR124172A1 (https=) |
| AU (1) | AU2021389180A1 (https=) |
| CA (1) | CA3203285A1 (https=) |
| CL (1) | CL2023001534A1 (https=) |
| CO (1) | CO2023008271A2 (https=) |
| CR (1) | CR20230415A (https=) |
| DO (1) | DOP2023000107A (https=) |
| EC (1) | ECSP23048974A (https=) |
| IL (1) | IL303209A (https=) |
| JO (1) | JOP20230118A1 (https=) |
| MX (1) | MX2023006318A (https=) |
| PE (1) | PE20231986A1 (https=) |
| TW (1) | TWI911340B (https=) |
| WO (1) | WO2022114164A1 (https=) |
| ZA (1) | ZA202305845B (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067360A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 一种DGKzeta拮抗剂及其在医药上的应用 |
| WO2025082460A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海先祥医药科技有限公司 | 二酰基甘油激酶抑制剂化合物及其应用 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CR20230415A (es) * | 2020-11-30 | 2023-09-08 | Kotobuki Pharmaceutical Co Ltd | Compuesto de heteroarilcarboxamida |
| US20250312341A1 (en) | 2022-06-20 | 2025-10-09 | Astellas Pharma Inc. | Methods for treating patients with locally advanced and/or metastatic solid tumors using a dgk zeta inhibitor |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US20240217989A1 (en) * | 2022-11-18 | 2024-07-04 | Incyte Corporation | Heteroaryl Fluoroalkenes As DGK Inhibitors |
| TW202428575A (zh) * | 2023-01-12 | 2024-07-16 | 美商英塞特公司 | 作為ｄｇｋ抑制劑之雜芳基氟代烯烴 |
| EP4661869A1 (en) | 2023-02-06 | 2025-12-17 | Bayer Aktiengesellschaft | Combinations of dgk (diacylglycerol kinase) inhibitors and immune checkpoint inhibitors and modulators |
| CN120826398A (zh) * | 2023-03-30 | 2025-10-21 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的化合物 |
| CN120826393A (zh) * | 2023-04-06 | 2025-10-21 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050266510A1 (en) * | 2004-01-08 | 2005-12-01 | Gajewski Thomas G | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| JP2008528520A (ja) * | 2005-01-25 | 2008-07-31 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
| CN101426774A (zh) * | 2006-04-19 | 2009-05-06 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| JP2009524677A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
| CN101578275A (zh) * | 2006-10-31 | 2009-11-11 | 先灵公司 | 苯胺基哌嗪衍生物及其使用方法 |
| WO2020006018A1 (en) * | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
| CN111372926A (zh) * | 2017-09-06 | 2020-07-03 | 普罗佩纶治疗公司 | Wdr5蛋白质-蛋白质结合的抑制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR120896A1 (es) | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| CN115697980B (zh) | 2020-04-24 | 2025-03-21 | 拜耳公司 | 作为dgkzeta抑制剂用于免疫活化的取代的氨基噻唑 |
| CR20230415A (es) | 2020-11-30 | 2023-09-08 | Kotobuki Pharmaceutical Co Ltd | Compuesto de heteroarilcarboxamida |
-
2021
- 2021-11-29 CR CR20230415A patent/CR20230415A/es unknown
- 2021-11-29 EP EP21898136.3A patent/EP4253373A4/en active Pending
- 2021-11-29 CA CA3203285A patent/CA3203285A1/en active Pending
- 2021-11-29 TW TW110144382A patent/TWI911340B/zh active
- 2021-11-29 PE PE2023001705A patent/PE20231986A1/es unknown
- 2021-11-29 KR KR1020237021502A patent/KR20230116838A/ko active Pending
- 2021-11-29 AU AU2021389180A patent/AU2021389180A1/en active Pending
- 2021-11-29 JP JP2022565480A patent/JP7397452B2/ja active Active
- 2021-11-29 US US18/254,829 patent/US20240043403A1/en active Pending
- 2021-11-29 AR ARP210103290A patent/AR124172A1/es unknown
- 2021-11-29 CN CN202180080083.8A patent/CN116528864A/zh active Pending
- 2021-11-29 MX MX2023006318A patent/MX2023006318A/es unknown
- 2021-11-29 WO PCT/JP2021/043540 patent/WO2022114164A1/ja not_active Ceased
- 2021-11-29 IL IL303209A patent/IL303209A/en unknown
-
2023
- 2023-05-29 CL CL2023001534A patent/CL2023001534A1/es unknown
- 2023-05-29 DO DO2023000107A patent/DOP2023000107A/es unknown
- 2023-05-30 JO JOJO/P/2023/0118A patent/JOP20230118A1/ar unknown
- 2023-05-31 ZA ZA2023/05845A patent/ZA202305845B/en unknown
- 2023-06-23 CO CONC2023/0008271A patent/CO2023008271A2/es unknown
- 2023-06-29 EC ECSENADI202348974A patent/ECSP23048974A/es unknown
- 2023-11-28 US US18/521,400 patent/US12077519B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050266510A1 (en) * | 2004-01-08 | 2005-12-01 | Gajewski Thomas G | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| JP2008528520A (ja) * | 2005-01-25 | 2008-07-31 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いる化合物 |
| JP2009524677A (ja) * | 2006-01-25 | 2009-07-02 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物 |
| CN101426774A (zh) * | 2006-04-19 | 2009-05-06 | 安斯泰来制药有限公司 | 唑类甲酰胺衍生物 |
| CN101578275A (zh) * | 2006-10-31 | 2009-11-11 | 先灵公司 | 苯胺基哌嗪衍生物及其使用方法 |
| CN111372926A (zh) * | 2017-09-06 | 2020-07-03 | 普罗佩纶治疗公司 | Wdr5蛋白质-蛋白质结合的抑制剂 |
| WO2020006018A1 (en) * | 2018-06-27 | 2020-01-02 | Bristol-Myers Squibb Company | Substituted naphthyridinone compounds useful as t cell activators |
Non-Patent Citations (1)
| Title |
|---|
| VELNATI, S等: "Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 164, 15 February 2019 (2019-02-15), pages 378 - 390 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067360A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 一种DGKzeta拮抗剂及其在医药上的应用 |
| WO2025082460A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海先祥医药科技有限公司 | 二酰基甘油激酶抑制剂化合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023006318A (es) | 2023-06-14 |
| CA3203285A1 (en) | 2022-06-02 |
| DOP2023000107A (es) | 2023-07-16 |
| ZA202305845B (en) | 2024-09-25 |
| JP7397452B2 (ja) | 2023-12-13 |
| AU2021389180A9 (en) | 2024-06-13 |
| US12077519B2 (en) | 2024-09-03 |
| IL303209A (en) | 2023-07-01 |
| WO2022114164A1 (ja) | 2022-06-02 |
| KR20230116838A (ko) | 2023-08-04 |
| PE20231986A1 (es) | 2023-12-12 |
| EP4253373A1 (en) | 2023-10-04 |
| AU2021389180A1 (en) | 2023-06-29 |
| CL2023001534A1 (es) | 2023-11-10 |
| CR20230415A (es) | 2023-09-08 |
| EP4253373A4 (en) | 2024-11-13 |
| US20240043403A1 (en) | 2024-02-08 |
| CO2023008271A2 (es) | 2023-07-21 |
| ECSP23048974A (es) | 2023-07-31 |
| AR124172A1 (es) | 2023-02-22 |
| TW202229256A (zh) | 2022-08-01 |
| TWI911340B (zh) | 2026-01-11 |
| US20240101532A1 (en) | 2024-03-28 |
| JPWO2022114164A1 (https=) | 2022-06-02 |
| JOP20230118A1 (ar) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116528864A (zh) | 杂芳基甲酰胺化合物 | |
| CN113365994B (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| CA3026602C (en) | Pyrrolopyrimidine crystal for the preparation of a JAK inhibitor | |
| AU2015266453C1 (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| CN111801328A (zh) | 自分泌运动因子抑制剂及其用途 | |
| EP3768272B1 (en) | Jak inhibitors | |
| TW201305160A (zh) | 作為新的ＳｙＫ抑制劑的取代的吡啶并吡嗪化合物 | |
| KR20190002468A (ko) | N-[2-(3-히드록시-3-메틸부틸)-6-(2-히드록시프로판-2-일)-2h-인다졸-5-일]-6-(트리플루오로메틸)피리딘-2-카르복스아미드의 결정질 형태 | |
| JP2014510768A (ja) | Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン | |
| WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| KR102958021B1 (ko) | 피리다지닐 티아졸카르복시아미드 화합물 | |
| HK40096740A (zh) | 杂芳基甲酰胺化合物 | |
| HK40085586A (en) | Pyridazinyl thiazolecarboxamide compound | |
| EA047776B1 (ru) | Соединение гетероарилкарбоксамида | |
| HK40084227A (zh) | 哒嗪基噻唑甲醯胺类化合物 | |
| TWI401258B (zh) | 吡咯並嘧啶類化合物及其用途 | |
| HK40085586B (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| HK40084227B (zh) | 哒嗪基噻唑甲醯胺类化合物 | |
| HK40059656B (zh) | 哒嗪基噻唑甲酰胺类化合物 | |
| HK40059656A (en) | Pyridazinyl thiazolecarboxamide compound | |
| HK40077526B (zh) | 对核受体具有活性的化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40096740 Country of ref document: HK |